Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
Sign Up to like & getrecommendations! Published in 2018 at "BMC Health Services Research"
DOI: 10.1186/s12913-018-3398-x
Abstract: BackgroundCongenital haemophilia A (HA) is a rare, inherited, life-long bleeding disorder characterised by prolonged or spontaneous bleeding due to the lack of clotting factor VIII (FVIII) in the body. Treatment for HA involves FVIII replacement… read more here.
Keywords: impact; treatment; analysis; health ... See more keywords
Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.692157
Abstract: The most challenging complication associated with Factor VIII (FVIII) replacement therapy is the development of neutralizing anti-drug antibodies, or inhibitors, which occur in 23-35% of severe (FVIII level read more here.
Keywords: factor; anti fviii; rfviiifc; factor viii ... See more keywords